pSLIK_Hyg_mTurquoise2_Atg4BC74A
(Plasmid
#161733)
-
PurposeDoxycycline-inducible expression of Atg4B(C74A) fused with mTurquoise2 to inhibit autophagy
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 161733 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepSLIK-hygro
-
Backbone manufacturerAddgene #25737
- Backbone size w/o insert (bp) 12262
- Total vector size (bp) 14694
-
Vector typeMammalian Expression, Lentiviral ; destinatioin vector for gateway cloning
-
Selectable markersHygromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature30°C
-
Growth Strain(s)NEB Stable
-
Growth instructionsAfter plasmid purification, please make sure your plasmid contains 7 repeats of TetO sequence as this region can occasionally be lost by recombination.
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameAtg4B(C74A) (Atg4b Mouse)
-
Alt nameAtg4B
-
SpeciesM. musculus (mouse)
-
Mutation220-222 TGC (Cys) is changed to GCA (Ala)
-
GenBank IDNM_174874
-
Entrez GeneAtg4b (a.k.a. 2510009N07Rik, Apg4b, Atg4bl, Autl1, MmAPG4B)
-
Tag
/ Fusion Protein
- mTurquoise2 (N terminal on insert)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer attB1
- 3′ sequencing primer attB2 (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pSLIK_Hyg_mTurquoise2_Atg4BC74A was a gift from Alec Kimmelman (Addgene plasmid # 161733 ; http://n2t.net/addgene:161733 ; RRID:Addgene_161733) -
For your References section:
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ, Banh RS, Paulo JA, Wen KW, Debnath J, Kim GE, Mancias JD, Fearon DT, Perera RM, Kimmelman AC. Nature. 2020 May;581(7806):100-105. doi: 10.1038/s41586-020-2229-5. Epub 2020 Apr 22. 10.1038/s41586-020-2229-5 PubMed 32376951